Many different types of cancer show a high incidence of TP53 mutations and some of them may acquire oncogenic functions that underline the aggressive phenotype of breast cancer, pancreatic cancer, and non-small cell lung cancer, therefore providing numerous exciting therapeutic possibilities [138]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.